Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293
Shots:
- NMS to receive ~$65M up front and option exercise fees & is also eligible to receive an additional fee upon achievement of development, regulatory and commercial milestones along with royalties on net sales
- If option exercise, Merck KGaA gets an exclusive right to research, develop, manufacture, and commercialize NMS-293. Additionally, both companies collaborated on the clinical development of NMS-293 with NMS designing, sponsoring, conducting, and funding global clinical trials
- NMS-293 is currently being evaluated in a P-I study as monothx. for BRCA-mutated tumors and in combination with temozolomide in recurrent glioblastoma
Ref: Businesswire | Image: Merck KGaA
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
